News
COVID-19 symptoms were more commonly mild and limited to the upper respiratory tract among patients with vs without preexisting immunity at the time of infection, including when immunity was induced ...
The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback